In addition, consistent with the above conclusion that Musashi-2 expression was negatively correlated with immunosuppressive factors, TIDE scores were used to predict the tumor response to ICB treatment, and patients with lower Musashi-2 expression were found to be more responsive to ICB treatment (Figure 7G). The gene discussed is MSI2; the disease is neoplasm.